Compound ID | 3407
NTCM-M3
Synonym(s): VP20621| NTCM M3 | NTCMM3
| Agent Type: | Indirect acting; |
| Spectrum of activity: | Gram-positive |
| Target Pathogen: | Active against Clostridioides difficile; indicated for recurrent C. difficile infection |
| Description: | Nontoxigenic Clostridium difficile spores of restriction endonuclease analysis (REA) type M3; a microbiome modulating agent |
| Institute where first reported: | Destiny Pharma; Sebela Pharmaceuticals |
| Year first mentioned: | 2012 |
| Highest developmental phase: | Phase 2 (NCT01259726) |
| Development status: | Active |
| External links: | |
| Citation: | https://journals.asm.org/doi/10.1128/aac.00913-12 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.